Related Experiment Video

Updated: Jul 6, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Chimeric antigen receptor T-cell therapy and fludarabine: precision dosing imperatives

Sebastian G Wicha1, Eva M A Wansing1,2,3, Adrin Dadkhah2,3

  • 1Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.

Blood Advances
|January 8, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

863

Related Experiment Videos

Last Updated: Jul 6, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

863

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

Articles linked to this work by shared authors, journal, and citation graph.

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Bone marrow transplantation·2026

Effects of malaria intermittent preventive treatment with dihydroartemisinin-piperaquine on antiretroviral drug concentrations in African pregnant women living with HIV.

Antimicrobial agents and chemotherapy·2026

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026

Prospective study of pharmacokinetics of isavuconazole in critically ill patients undergoing continuous hemodialysis with and without acute-on-chronic liver failure.

Annals of intensive care·2026

Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial.

Nature medicine·2026

The SF3b complex in cancer: structural basis, molecular mechanisms, and therapeutic opportunities.

Blood advances·2026

Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysis.

Blood advances·2026

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

Blood advances·2026

The hematology workforce in the United States: past, present, and strategies for the future.

Blood advances·2026

Chronic xenogeneic GVHD after CAR T cell therapy limits long-term safety assessment of CAR effects using NSG mouse model.

Blood advances·2026

Modifying quality and equity of care: emerging roles of genetic disease modifiers in β-hemoglobinopathies.

Blood advances·2026

Robotic gastric Roux-en-Y bypass with or without concomitant cholecystectomy: pilot open label randomized trial.

BJS open·2026

The Relationship of CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes and Their Ratios With Clinicopathological Parameters and Tumor Budding in Esophageal Squamous Cell Carcinoma.

International journal of surgical pathology·2026

Reduced Versus Full Lead-In Apixaban or Rivaroxaban in Acute Venous Thromboembolism: A Systematic Review.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026

FOLFOXIRI Plus Panitumumab for Left-sided RAS-wild-type Metastatic Colorectal Cancer.

The oncologist·2026

Nanoparticles for fluorescence-guided breast cancer surgery: advances in in vivo preclinical research.

Nanomedicine (London, England)·2026

Clamshell and Hemiclamshell Incisions for Complex Intrathoracic Tumors: A Retrospective Analysis of Indications and Outcomes.

Thoracic cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us